Spermosens AB (publ) (NGM:SPERM)
Sweden · Delayed Price · Currency is SEK 0.0086
+0.0002 (2.38%)
At close: Sep 24, 2026
Spermosens AB Earnings Call Transcripts
Fiscal Year 2026
-
Clinical validation of the Generation 3 study is progressing, with strong partner interest and ambitions to sign commercial agreements by late 2026. The company is financially stable into 2027 and is preparing for scalable manufacturing and regulatory approval, while enhancing investor communications.
-
Product is ready for clinical validation and regulatory steps, with strong partner interest and a unique market position. Financial runway extends to late July, with licensing deals targeted for H2 2026 and no current plans for rights issues. Ongoing strategic focus is on partnerships, cost control, and value creation.